Dr. Jack Fincham presents as a defense-oriented expert witness with extremely limited public documentation, creating significant intelligence gaps for plaintiff attorneys. His credentials, institutional affiliation, and specific area of expertise remain undocumented in available records, which is unusual for an expert witness in major federal litigation. The absence of basic professional information suggests either a deliberately low public profile or limited academic/professional prominence. His sole documented appearances center exclusively on the National Prescription Opiate Litigation in the Northern District of Ohio in late 2022, where he testified for the defense in pharmaceutical liability matters, indicating likely expertise in pharmacology, public health, or pharmaceutical economics. Fincham's defense-side orientation is clear from his case history, appearing for defendants in 2 out of 3 documented cases within the opioid MDL. Notably, he has never faced a Daubert challenge, which could indicate either that his methodology is uncontroversial or that opposing counsel has not scrutinized his qualifications sufficiently. For plaintiff attorneys, this expert presents both opportunity and risk. The complete absence of Daubert challenges means there is no established precedent for excluding his testimony, but it also suggests his opinions may not be pushing controversial boundaries that would trigger such challenges. His narrow case history in opioid litigation may indicate specialized knowledge that could be valuable, but the lack of documented credentials raises questions about his qualifications that plaintiff counsel should exploit through aggressive voir dire and potential Daubert challenges focused on foundational expertise and methodology.
No Daubert challenges on record.
Free during beta. Your inquiry will be sent to MTAA and the expert if they've claimed their profile.
We'll send a verification link to your email. Once verified you can add contact info, bio, and availability.